US Pharm. 2018;43(6)(Generic Drugs suppl):6-8.
ABSTRACT: Patients may lack an understanding of generic drugs, which are determined to be equally as safe and effective as their branded counterparts by the FDA, as well in comparison studies. Because the FDA approval process for generic drugs requires fewer resources, generic drugs are less expensive and can help patients reduce prescription healthcare costs. Pharmacists are well positioned to guide both patients and clinicians in the appropriate use of generic drugs, and they therefore have the opportunity to address questions from their patients and enhance patients’ knowledge to encourage the use of generic drugs.
Patients may have a poor understanding of generic drugs, which can affect their willingness to use these agents. Pharmacists have the opportunity to identify patient concerns by encouraging their patients to ask questions, and they can clarify potential misconceptions about generic drugs via patient education. With open communication, pharmacists can improve patients’ knowledge and help them become more comfortable with using generic drugs.11 See TABLE 1 for a listing of frequently asked patients’ questions about generic drugs, as well as suggested patient-friendly responses that the pharmacist can provide.
The availability of generic drugs allows patients to purchase cheaper equivalents of brand-name drugs without compromising efficacy, safety, or quality. Therefore, the use of generics can greatly reduce healthcare costs associated with prescription-drug spending. Pharmacists can encourage patients’ acceptance of generics and provide information that helps patients understand the similarities and differences between generic and brand-name drugs, as well as guide clinicians in the appropriate use of generic drugs.
1. ASPE Issue Brief. Observations on trends in prescription drug spending. https://aspe.hhs.gov/sites/default/files/pdf/187586/Drugspending.pdf. March 8, 2016. Accessed March 14, 2018.
2. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: origins and prospects for reform. JAMA. 2016;316:858-871.
3. FDA. Development & approval process (drugs). www.fda.gov/Drugs/DevelopmentApprovalProcess/default.htm#FDA. Accessed March 16, 2018.
4. FDA. How drugs are developed and approved. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/default.htm. Accessed March 16, 2018.
5. FDA. Generic drugs: questions & answers. www.fda.gov/drugs/resourcesforyou/consumers/questionsanswers/ucm100100.htm#q1. Accessed March 15, 2018.
6. FDA. The generic drug approval process. www.fda.gov/Drugs/NewsEvents/ucm508150.htm. Accessed March 15, 2018.
7. U.S. Department of Health and Human Services. Approved Drug Products With Therapeutic Equivalence Evaluations, 38th ed. www.fda.gov/cder/orange/obannual.pdf. Accessed March 15, 2018.
8. Kesselheim AS, Misono AS, Lee JL, et al. Clinical equivalence of generic and brand-name drugs used in cardiovascular disease: a systematic review and meta-analysis. JAMA. 2008;300:2514-2526.
9. Shrank WH, Hoang T, Ettner SL, et al. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions. Arch Intern Med. 2006;166:332-337.
10. Kesselheim AS, Stedman MR, Bubrick EJ, et al. Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis. Drugs. 2010;70:605-621.
11. Sanchez CK, Zurek AM. Patient perceptions of generic drugs: dispelling misconceptions. US Pharm. 2016;41(6)(Generic Drug Review suppl):36-41.
12. Pope ND. Generic substitution of narrow therapeutic index drugs. US Pharm. 2009;34(6)(Generic Drug Review suppl):12-19.
13. Vivian JC. Generic-substitution laws. US Pharm. 2008;33(6)(Generic Drug Review suppl):30-34.